Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc boosted its stake in Arvinas, Inc. (NASDAQ:ARVN) by 19.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,770 shares of the company’s stock after buying an additional 4,850 shares during the period. Ensign Peak Advisors Inc’s holdings in Arvinas were worth $571,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. KBC Group NV increased its holdings in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after acquiring an additional 1,255 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Arvinas in the fourth quarter valued at approximately $171,000. Teacher Retirement System of Texas raised its holdings in shares of Arvinas by 19.0% during the fourth quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company’s stock valued at $274,000 after buying an additional 2,280 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Arvinas by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock worth $279,000 after buying an additional 1,367 shares during the period. Finally, Canada Pension Plan Investment Board bought a new position in Arvinas in the 4th quarter worth approximately $332,000. 95.19% of the stock is currently owned by institutional investors.

Arvinas Stock Up 3.7%

Shares of NASDAQ:ARVN opened at $6.49 on Friday. The company’s fifty day moving average is $7.69 and its two-hundred day moving average is $16.11. The company has a market cap of $473.71 million, a P/E ratio of -2.34 and a beta of 2.21. Arvinas, Inc. has a 12-month low of $5.90 and a 12-month high of $37.38.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Thursday, May 1st. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. The firm’s revenue was up 646.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.97) EPS. Equities research analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Insider Buying and Selling at Arvinas

In related news, CEO John G. Houston sold 31,338 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. This trade represents a 2.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Noah Berkowitz sold 8,658 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the transaction, the insider now owns 110,023 shares in the company, valued at approximately $945,097.57. This represents a 7.30% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,230 shares of company stock valued at $769,402 in the last 90 days. 4.73% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ARVN has been the topic of several recent analyst reports. Stifel Nicolaus cut their target price on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Guggenheim cut their price objective on shares of Arvinas from $32.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Jefferies Financial Group reaffirmed a “hold” rating and issued a $10.00 price objective (down previously from $52.00) on shares of Arvinas in a report on Friday, May 2nd. The Goldman Sachs Group lowered their target price on shares of Arvinas from $12.00 to $8.00 and set a “neutral” rating on the stock in a research note on Friday, May 2nd. Finally, Bank of America reduced their price target on shares of Arvinas from $54.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday, March 12th. Eight analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $20.92.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.